Clint Tomlinson
Vice President, Investor Relations
Replay available
Anavex Life Sciences (NASDAQ:AVXL) Q3 2020 earnings call, held 2020-08-06. Watch the replay and read the transcript on 6ix.

On 6ix: 6ix.com/event/anavex-life-sciences-corp-avxl-q3-2020-earnings-call
Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.
0:01 Welcome to the Anne of X Life Sciences to announce fiscal 2020 third quarter financial results conference call. My name is Rebecca and I will be your operator for today's call. At this time, all participants are in listen-only mode. Please note that this conference is being recorded. I will now turn the call over to Clint Tomlinson. Please go ahead.
0:23 Thank you and good morning, everyone. We appreciate you joining us today for Anne of X Life Sciences conference call and webcast. Dr. Christopher Mislin, President and Chief Executive Officer, and Sandra Boenisch, Principal Financial Officer. Dr. Misling and Ms. Boenisch will make prepared remarks, and then we will take questions from equity analysts.
1:13 Before we begin, please note that during this conference call, the company will make some projections and forward-looking statements regarding future events. We encourage you to review the company's filings with the SEC. This includes, without limitation, The company's forms 10-K and 10-Q, which identify the specific factors that may cause actual results or events to differ materially from those described in these forwarding statements. These factors may include, without limitation, risks inherent in the development and or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and Maintenance of Intellectual Property Rights.
2:01 And with that, I'd like to turn the call over to Dr. Misling.
2:05 Thank you. Thank you, everyone, for joining us on today's conference call to review our third quarter financial results and share with you some clinical updates for Annex 273 or La Camusie. During the last quarter since our last conference call, we have continued to advance our clinical programs with several key milestones accomplished. Just yesterday, we announced having received compassionate use, special access scheme, approval for Alzheimer's disease patients, continued treatment with Anavex 273 by the Australian Government Department of Health, Therapeutics Good Administration TGA, This is certainly an important milestone and we are honored to support medical professionals and their patients seeking treatment for Alzheimer's disease and who have very few medical options.
3:02 In June, we received approval from both the Canadian and the United Kingdom health authorities to expand the footprint of the International Phase 2B-3 Double-Blind Randomized Placebo-Controlled Safety and Advocacy Trial for the treatment of early Alzheimer's disease into Canada and the UK, respectively. Adding these global regions is expected to continue steadfast or even accelerated enrollment of this important Alzheimer's disease trial while also adding international footprint in North America and Europe. We announced in June the complete enrollment of the ANVEX 273 US Phase II Rett Syndrome trial. The enrollment target was surpassed by 50%.
3:53 with 31 patients now enrolled in this trial. We expect to announce top-line results from this study in calendar Q4 2020. Furthermore, just last month, we announced that the first patriotic patient was those in the third study of Rett syndrome program, the Excellence Trial. This Phase II-III trial will evaluate the safety and efficacy of Anavex 273 in over 69 patriotic patients with Rett syndrome, age 5 to 18, over a 12-week treatment period, incorporating Anavex 273 specific precision medicine biomarkers.
4:46 We were also pleased to report in July that the first participant was enrolled in a Phase 1 clinical trial of Anorex 371, which focused on the treatment of frontotemporal dementia , for which Anorex 371 was previously granted orphan drug designation by the FDA. The Phase 1 clinical trial is a prospective double-blind randomized placebo-controlled study. This study will be followed by longer duration dosing including STD patients and incorporating exploratory efficacy in disease biomarker measures. Topline data is anticipated in the first half of 2021. Finally, Parkinson's disease dementia top-line results from the Phase 2 study are forthcoming and are expected to be announced during this fiscal quarter.
5:39 And now, I would like to direct the call to Sandra Boenisch, Principal Financial Officer of Annex, for a brief financial summary of the recently reported quarter.
5:52 Thank you, Christopher, and good morning, everyone. We reported a net loss of $6.5 million or $0.11 per share during the quarter, as compared to $6.5 million or $0.13 per share in the comparable quarter of fiscal 2019. Our general and administrative expenses remained consistent quarter over quarter at $1.4 million. Research and development expenses were $6.7 million for the quarter ended June 30, 2020, an increase of $0.9 million over the comparable quarter in 2019, This increase is a result of increased clinical trial activities and the continued advancement of existing clinical trials. Our cash position at June 30, 2020, was $27.6 million, compared to $22.2 million at September 30, 2019.
6:44 Thank you, and now I will turn the call back over to Christopher.
6:48 Thank you, Sandra. In some way, I would like to point out that despite these challenging times, We continue to make steady progress with fiscal responsible work towards reaching several important milestones and we are poised for an exciting time ahead with multiple data readouts ahead of us. We look forward to providing further updates as advancements continue. I would now like to open the call for questions. Operator, please go ahead. Thank you. We will now begin the question and answer session. If you have a question, please press star, then 1 on your touch-tone phone. If you wish to be removed from the queue, please press the pound sign or the hash key.
7:35 If you are using a speakerphone, you may need to pick up the handset first, before pressing the numbers. Once again, if you have a question, please press star, then 1. and our first question is from Charles Duncan from Cancer Fitzgerald. Your line is open.
7:55 Good morning, Christopher. Thanks for taking the questions and congratulations on the progress in the quarter. Wanted to ask you a couple of questions. First of all, regarding the PD cognition study, what would you look for out of that study to give you confidence to continue to invest in that particular indication. It seems like PD is, or particularly cognition in PD is somewhat of a heterogeneous indication. I'm just wondering how you would define success.
8:37 We are doing the study from the background that we had a signal in our phase 2A Alzheimer's disease We then had in parallel a Michael Fox Foundation-sponsored clinical study in an animal model of disease modification of Parkinson's. So when this data came together and the outcome were considered sufficiently positive to explore these features in one study, that's where the advice from advisors, scientific advisors from Michael Fox Foundation came about to do and execute this study. So it's a combination of looking for cognition, but also looking for features of Parkinsonian disease, if that can be alleviated with the drug Anorex 273.
9:33 And we decided to shift the focus on the dementia part. So the primary endpoint is looking at the dementia domain. and the secondary endpoints are those which are more considered the Parkinsonian impairment like UPDRS as well as sleep, ASGRAF data including in motor impairment features as well as very heavily biomarker including biomarker measures which even goes beyond the classical biomarkers because we're also including the entire genome, including the RNA and the DNA. So I think once we have the data, we'll be able to hopefully be very aware of what's going on in this study.
10:28 Yeah. So just if I could follow up. So it sounds like you look for a signal in terms of The dementia component or cognition component, so you look for that. And perhaps you'd look for a lack of signal or impact on UPDRS in terms of impairment. And would you hope to see any improvement? I mean, I could easily see you seeing some improvement in, for example, sleep parameters.
11:03 Right. We don't want to exclude anything. We just really take this as a very objective study to look at what happens in the study when treated with anodexin 3 versus control. And this is what we really look forward to seeing.
11:23 So it's very much a signal-seeking study. You don't have any biases in terms of effect size or anything that you're thinking about?
11:34 Right, we just want to see a signal first and that could be however it is and that would be then certainly we can move from there by sharing with the regulatory bodies and take it from there since it's highly unneeded since now almost 80% of all Parkinson's patients develop dementia.
11:58 Okay, and I think you mentioned that data should be by the end of September?
12:03 We said this quarter, you know, so it will definitely be this quarter. I don't want to go in more specifics. We will report exactly when we have the data.
12:14 Yeah, that's cool. Last question then regarding the first RET study, the U.S. Phase II. Can you provide any color on the types of patients that were enrolled. Any characteristics that kind of broadly can help us understand that study enrollment and what you'd look for out of it?
12:40 Yeah. So we had the benefit of having already a glimpse of the data in the first cohort, which was the PK cohort of six patients. And in this cohort, Transcription by CastingWords We make sure that because this is also a complex disease that we include patients which are able to show an improvement over the various phenotypes of the disease, which is very broad. It ranges from movement impairment to features of cognitive impairment, of response, of seizures, of sleep impairment, of startling and breathing impairments. So you want to make sure that you include patients who have some level of dysfunction in order then to be able to discern an effect with the drug.
13:45 Sure. And you feel like the enrollment when consistent to the protocol requirements?
13:56 Yes. So we have made sure that we have always looked for every patient Thank you very much. Thank you.
14:20 But beyond that, when you think about the sample for that first U.S. trial, how does that sample relate to the broader set of patients, the red patients? Do you think that you've captured a fairly... Good SAT or good broad coverage on the entire population? Are you hitting a certain niche that really can be useful to determining the potential use of 273 in that population?
14:53 Yeah, so the U.S. study is 18 years and older, and it sounds like very generous, but the reality is there's actually less patients pool for study available in older patients for various reasons. and we basically are happy that we were able to involve especially in the last few months many more patients than we had actually planned for because we just had planned for 21 patients at the beginning and then we added up 10 more to end up now at 31 which is very beneficial for a calculation of the efficacy and so we were very pleased about that without having to give up any on the quality of the patients or participants in the study. So what we do know from scientific experience is that it is usually harder to find a change of phenotype in the older the patients are especially in neurodevelopmental diseases So that means if you treat earlier, it's likely that you are able to find a signal. So the fact that we already saw something in the first six patients in adults, in the adult study, but also with the lowest dose, it's kind of very encouraging.
16:25 Yeah, for sure. But it's a heterogeneous patient population, it sounds like, and again, should be... Thank you very much. Thank you.
16:54 I don't know if we can use it as a benchmark for the entire study. It would be great if so that would play out in the study and I think we will see when the study will read out which is as I mentioned by the end of this year latest.
17:09 Perfect. Okay Christopher thanks for taking my questions. We'll look forward to data flow over the second half of the year. Thank you. Your next question is from Ram from HC Wainwright. Your line is open. Morning. This is Maz speaking on behalf of Ram. Thanks for taking my questions. The first query relates to the Parkinson's disease dementia trial, and then I have a couple of follow-up pipeline questions. So firstly, what do you think in terms of What was the last question? Is the Phase 2 positive? I see.
18:16 So the answer to the first question, the CVR, continuity of attention, is the primary endpoint, and that is definitely the most relevant signal we are looking at for Parkinson's dementia. The UDRS is a, I would say, a composite of multiple measures, among them the movement, among them also function, and, to a certain extent, Activities of Daily Living. So that's why it's structured in different subscales, like 1, 2, and 3, and 3 being the movement subscale. So we believe that CBR, Concealed Attention, will give us the most important signal for the dementia, Parkinson's dementia domain.
19:15 but also the other one will be interesting. That's why we included it as a secondary in court. And in terms of your second question, if the phase two is positive, we would share it with the FDA and then take the steps from there. What would be the right way to approval? The appropriate next step for seeking approval. Okay, makes sense. And Has the longer-term dosing study using the exploratory efficacy and disease biomarker measures been initiated? As the longer-term dosing study using the exploratory efficacy and disease biomarker measures, has that been initiated?
20:03 You mean the extension, when you say longer-term? Yeah. So we have in all our studies an extension. So both the U.S. Rett Syndrome Study as well as the Parkinson's Dementia Study have an extension and so the extension for the Rett Syndrome Study is 12 weeks in the U.S., one year the Avatar Study and it will be also one year in the Excellence Study in Rett Syndrome and it's one year in the Parkinson's Dementia Study and it's two years in the Alzheimer's 2D-3 Study. All these extension studies have not only the biomarkers but also the underlying randomized placebo control studies have the biomarker including the genetic analysis included. So we don't have to wait for weed out of the extension study to learn about that.
21:03 Makes sense. And just finally in terms of Are you looking at other CNS disorders such as epilepsy?
21:15 Right. So when you look at our pipeline, you might have noticed that we have also strong evidence of animal model conservatory efficacy for Parkinson's, for infantile spasm. for Fragile X, for Angelman Syndrome, and these indications will likely be next in line in case of we have a positive readout on the ongoing studies. So the franchise will expand into this indication since this is something which practically has been are shown to be already a very strong signal with Anavex 2 symmetry.
22:11 Fantastic. I feel very excited. Thanks for taking my question.
22:16 You're welcome. Thank you. I'm going to need an interruption. If you have a question, please press star, then 1. Charles, your line is open.
22:30 Yeah, hi. I haven't heard anyone. Hopefully Christopher's still on the line. Thanks for taking the follow-up. Just one quick follow-up on the pediatric program. I'm just wondering if you could give us any further indication of the types of patients that you'd like to enroll in that. Obviously, there's a certain age group, 5 to 18. We can read what's on ClinTrials. But I'm just wondering if when you talk to investigators... if there is a certain phenotype that you would like to see enrolled in that that could give you confidence in the outcome but also address really the underlying unmet gen needs.
23:18 So the patriotic study from 5 to 18 years old is relatively comparable to the adult studies Once the phenotype shows up in Rett syndrome, it very much stays relatively stable with some variations of that. So you're looking at similar measures including the ISPQ, the CGII, and the sleep parameter. And the question is actually identical In the adult and in the children, because of the phenotype of the red population, the adults are still considered children. So we have in our excellent study, because it's a larger study and it's geared towards a pivotal study, that's why it's a phase two, phase three, we have more measures included, and it's slightly longer.
24:21 So the adult studies are seven weeks in duration, and the periodic study is 12-week duration.
24:31 Okay, that's helpful. And then just if you could wax poetic, if you will, or speculate on the competitive environment, you know, there are other programs. We did recently see one recommence enrollment from the Neuron Acadia side we also know GW is doing some work on RET and it would seem to me that RET is large unmet need but in an orphan disorder and I'm just wondering if you could give us a sense of the feedback that you've gotten from the advocacy community on how 273 fits within the emerging treatment paradigm assuming all of these programs are successful which is a big leap But the other thing is in terms of competition for patients in the programs.
25:32 So the comment I'd like to give is that from the very beginning, we were fortunate that we were highly supported by the RET community, the foundation itself. actually was instrumental in even getting us where we are. Without them, we wouldn't have had any data in Rett syndrome to begin with. The entire preclinical animal model were supported and financially supported and paid for by the foundation. Without them, we wouldn't have had the data. And then when the data was very positive in the animal model of Rett syndrome, then the decision was made by the RET Foundation to also support our RET clinical study. So I'd like to thank the RET Foundation for that very much.
26:23 We also made something probably a very important distinction as we learned also during the COVID time which was extremely advantageous in hindsight. We just didn't send out the protocol and started the study without feedback from the parents of over-dried patients. So what we did, we basically asked them, what is important for you as a parent in your respective girl to participate in the study? We learned that visits in the hospital were considered very burdensome. So I basically decided to then to limit the visits in the hospital and also adding A optionality in the protocol that every visit can also be accepted at the home of the child.
27:18 And that was interesting because when COVID came along, we were able to switch to that manifestation or protocol optionality, and that also probably led to our ability to increase our enrollments. to buy 50% instead of stopping the trial entirely, which I understand other trials were forced to do.
27:46 Yes, certainly that makes it less complex in terms of interpreting the data, but it also seems like you facilitated progress with the rec community and perhaps that will bode well for the future.
28:03 And we plan to continue to do that, both with the foundation here in the US very much, but also abroad in Australia. We're working with the Rex Community Foundation in Australia as well as in Europe, in the UK as well. So we really are hand-in-hand working towards this goal of making sure that we don't do this in a vacuum.
28:32 Last question is does one see RET as being a challenge to Asian communities and is there any corporate strategy to broaden potential access to those countries through maybe partnering or other endeavors?
28:58 There is indeed the same amount of RET Patients in Asia, especially in Japan and China, but especially in Japan, there's the same amount of patients there than here in the US. So it's around about 10,000 to 15,000 patients in Japan alone. and we do plan after the readout of the U.S. study which is forthcoming to then move into the Japanese territory to also continue the study with Onivex 273 in red patients in that regard.
29:37 And would those be studies you'd conduct or do you think it may be best to do that in collaboration with the partners?
29:47 Right. So, you know, Japan is a unique market where the entity is working, has to be local. So they are probably a mix of a local sponsor with us together or to a CRO. We have not made a final decision on that yet.
30:07 Okay, good. Well, thanks for taking my follow-ups, Christopher. You're welcome. We have no further questions at this time. We have no further questions at this time.
30:38 So with that, we thank everybody to participate and this concludes today's conference. Thank you very much for participating. Thank you, ladies and gentlemen. This concludes today's conference. You may now disconnect.
Follow Anavex Life Sciences Corp. into a list and get an email when it puts out news.
Vice President, Investor Relations
President and Chief Executive Officer
Principal Financial Officer
Analyst, Cantor Fitzgerald